
Early Treatment Clears Virus in Second HIV-Infected Baby
A child born infected with HIV in California began treatment hours after birth, and is clear of virus 9 months later.
A child born infected with HIV in California began treatment hours after birth, and is clear of virus 9 months later.
Just one year after
On March 5, a team of researchers announced at the annual Conference on Retroviruses and Opportunistic Infections that a child born 9 months ago in Long Beach, California,
“In a second infant, cART by four hours of life led to rapid clearance of replicating virus and an undetectable proviral DNA by clinical assays within 6 days of life, supporting restriction of HIV spread with very early cART,” researchers wrote in the case abstract.
Researchers also announced at the conference that the Mississippi child, now 3 years old, remains free of the virus despite having being off of treatment for 21 months.
The Mississippi child was born prematurely in July 2010 to a mother who had not seen a doctor during her pregnancy and was unaware she was infected with HIV. Her baby reportedly tested positive for the virus at 30 hours of age. Soon thereafter, the child began antiretroviral therapy with 3 drugs: zidovudine, lamivudine, and nevirapine, as opposed to the standard prophylactic treatment.
One week after birth, the baby was discharged from the hospital and placed on antiretroviral therapy that included zidovudine, lamivudine, and co-formulated lopinavir-ritonavir. Treatment of the child ceased at the age of 18 months for undisclosed reasons.
When the child returned for further evaluation 5 months later, doctors anticipated finding high levels of the virus but instead found it to be nonexistent on standard tests. The child was later found to be
In the newly reported California case, the child’s mentally ill mother has advanced AIDS and failed to take the drugs prescribed to protect her baby during pregnancy
A clinical trial will soon begin in which approximately 60 babies born infected with
“Development of sensitive laboratory markers and standardized approaches will be necessary to guide the optimal management of very early HIV treated infants in order to achieve remission,” the researchers wrote in their abstract.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.














































































































































































































